title: A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series.
abstract: BACKGROUND
  The combination chemotherapy regimen of streptozocin and 5-fluorouracil (FU/STZ) has been used for the treatment of metastatic neuroendocrine tumours.
  
  
  OBJECTIVE
  The aim of this study was to analyse the use of this regimen in a tertiary oncology referral centre over a 10-year period.
  
  
  METHODS
  We retrospectively analysed nine cases from February 2000 to May 2010. Patient demographics, chemotherapy schedule, toxicities, progression-free and overall survival were tabulated for each patient.
  
  
  RESULTS
  The median progression-free survival was 17 months (range 3-48+ months), and overall survival 31 months (range 12-53+ months) with no toxicity related deaths.
  
  
  CONCLUSIONS
  FU/STZ was a well-tolerated regimen that produced significant benefit in the setting of metastatic and progressive disease. Our case series demonstrated comparable progression-free survival and overall survival in relation to randomized controlled studies and previous case series.
authors: Trinity College Dublin, St. James's Hospital, James's Street, Dublin 2, Ireland. jarushka_14@yahoo.com
authors: J
authors: J
authors: Naidoo
authors: D
authors: D
authors: O'Toole
authors: M J
authors: MJ
authors: Kennedy
authors: J V
authors: JV
authors: Reynolds
authors: M
authors: M
authors: O'Connor
authors: K
authors: K
authors: O'Byrne
mesh_terms: D007516:Adenoma, Islet Cell; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000556:secondary; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000556:secondary; D013311:Streptozocin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D013311:Streptozocin; D005472:Fluorouracil